Skip to main content
main-content
Top

05-03-2019 | EMA | News

approvalsWatch

Lorlatinib given European NSCLC approval

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: The ALK inhibitor lorlatinib has received a positive opinion from the EMA for use in patients with advanced ALK-positive non-small-cell lung cancer (NSCLC).

The recommendation for conditional marketing authorisation states that lorlatinib monotherapy may be given to patients who have progressed after first-line ALK inhibitor therapy with alectinib or ceritinib, or who have used crizotinib and at least one other ALK tyrosine kinase inhibitor.

Lorlatinib has previously been approved for these indications by the US FDA.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

See also:

share
SHARE
print
PRINT

ESMO 2022 congress coverage

Access the latest news and expert insight from the 2022 European Society for Medical Oncology Congress

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.